Clinical Trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Protocol Amendment History 14 changes
notable Trial sites expanded: 150 -> 155 locations 2026-07-28
notable Trial sites expanded: 145 -> 150 locations 2026-07-21
notable Trial sites expanded: 138 -> 145 locations 2026-07-11
notable Trial sites expanded: 135 -> 138 locations 2026-07-03
notable Trial sites expanded: 130 -> 133 locations 2026-06-24
notable Trial sites expanded: 125 -> 130 locations 2026-06-13
notable Trial sites expanded: 115 -> 125 locations 2026-06-09
notable Trial sites expanded: 107 -> 115 locations 2026-06-02
notable Trial sites expanded: 96 -> 107 locations 2026-05-23
notable Trial sites expanded: 91 -> 96 locations 2026-05-16
notable Trial sites expanded: 87 -> 91 locations 2026-05-09
notable Trial sites expanded: 83 -> 86 locations 2026-04-24
notable Trial sites expanded: 64 -> 81 locations 2026-04-10
notable Trial sites expanded: 61 -> 64 locations 2026-04-08
Trial Details
NCT Number NCT07216703
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Conditions Cervical Cancer
Enrollment 1,023 participants
Start Date 2026-01-19
Primary Completion 2031-10-29 (estimated)
Study Completion 2031-10-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-07